After progression on osimertinib, do you recommend overlapping TKI with 2nd line chemotherapy to avoid accelerated disease progression?

I do not continue the EGFR TKI in patients once clear evidence of clinical and radiologic progression makes me recommend a switch from an EGFR TKI to chemotherapy. This approach is considered due to reports regarding the potential tumor flare phenomena noted upon discontinuation of EGFR TKIs. There ...